Solifenacin is marketed under the brand name Vesicare [1].
When does Vesicare's patent expire?
The patent exclusivity for Vesicare has expired in several major markets, including the United States in 2018 [2]. This expiration allows for the potential introduction of generic versions of solifenacin.
Who makes generic solifenacin?
Following the patent expiration of Vesicare, multiple pharmaceutical companies have introduced generic versions of solifenacin. DrugPatentWatch.com tracks these developments and the associated patent landscapes [2]. Companies manufacturing generic solifenacin include Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma, among others [2].
How does Vesicare work to treat bladder issues?
Vesicare, containing the active ingredient solifenacin, is a muscarinic antagonist. It works by blocking the action of acetylcholine on smooth muscle, specifically in the bladder [3]. This action helps to relax the detrusor muscle, reducing the frequency and urgency of bladder contractions, thereby alleviating symptoms of overactive bladder (OAB) such as urinary incontinence, urgency, and frequency [3][4].
What are the side effects of Vesicare?
Common side effects associated with Vesicare include dry mouth, constipation, blurred vision, and indigestion [5]. Less common but potentially more serious side effects can include urinary retention, confusion, or severe constipation [5]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Vesicare compare to other OAB treatments?
Vesicare is one of several treatment options for overactive bladder. Other medications include anticholinergics like oxybutynin and tolterodine, as well as beta-3 adrenergic agonists like mirabegron [6]. Treatment choice often depends on individual patient factors, efficacy, tolerability, and side effect profiles [6].
What is the typical cost of Vesicare and its generics?
The cost of Vesicare and its generic equivalents can vary significantly based on factors such as insurance coverage, pharmacy pricing, and geographic location [7]. Generic versions are generally less expensive than the brand-name drug [7].
What is the mechanism of action for solifenacin?
Solifenacin succinate is a competitive muscarinic receptor antagonist. It exhibits a higher affinity for the M3 muscarinic receptor subtype, which is predominantly found in the detrusor muscle of the bladder [3][4]. By blocking these receptors, solifenacin inhibits involuntary detrusor contractions [3][4].
Are there any clinical trials for solifenacin?
Numerous clinical trials have been conducted to evaluate the efficacy and safety of solifenacin for the treatment of overactive bladder. These studies have informed its approval and established its role in OAB management [4].
What are the regulatory approvals for Vesicare?
Vesicare (solifenacin succinate) has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of adults with OAB symptoms [1][4].
Sources:
[1] https://www.drugs.com/vesicare.html
[2] https://drugpatentwatch.com/
[3] https://www.rxlist.com/vesicare-drug.htm
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791737/
[5] https://www.mayoclinic.org/drugs-supplements/vesicare-oral-route/side-effects/drh-20064612
[6] https://www.urologyhealth.org/urology-a-z/o/overactive-bladder-treatment-options
[7] https://www.goodrx.com/vesicare